Israel-based AION Labs, a collaborative effort between global pharmaceutical and technology firms focusing on AI-enabled drug discovery, has unveiled CombineAble.AI, a startup aimed at accelerating therapeutic development by tackling challenges in antibody design through a platform integrating AI with computational biomolecule simulations, utilising data from AION Labs' partners and publicly available sources.
CombineAble.AI emerges from an AION Labs startup challenge and plans to harness various advanced machine learning models, including protein language models, molecular dynamics simulations, and optimization algorithms, with support from AION Labs' resources and expertise to refine its scientific strategy, expand its team, and leverage insights from pharmaceutical partners for future development and commercialization. This announcement reflects a broader trend in AION Labs' venture studio, which encompasses startups like DenovAI, Promise Bio, TenAces, and OMEC.AI, all oriented towards research and therapeutic advancement, ranging from antibody discovery to precision medicine and drug candidate assessment.
Click here to read the original news story.